Low doses of losartan, an FDA-approved generic hypertension medication, may improve the results of nanotherapeutic approaches to cancer treatment by modifying the network of abnormal collagen fibers that characterizes most solid tumors.
Low doses of losartan, an FDA-approved generic hypertension medication, may improve the results of nanotherapeutic approaches to cancer treatment by modifying the network of abnormal collagen fibers that characterizes most solid tumors.